Abbott Laboratories makes up approx 0.28% of Provise Management Group’s portfolio.Catawba Capital Management Va boosted its stake in ABT in the latest quarter, The investment management firm added 2,370 additional shares and now holds a total of 35,191 shares of Abbott Laboratories which is valued at $1,500,896. The company reported the earnings of $0.55/Share in the last quarter where the estimated EPS by analysts was $0.53/share. Abbott Laboratories makes up approx 0.01% of Dividend Assets Capital’s portfolio.Carroll Financial Associates reduced its stake in ABT by selling 577 shares or 9.74% in the most recent quarter. The Abbott Park Illinois 60064 based company is now trading 25.64% above its 52 week low of $36 and -9.53% below its 52 week high of $49.51. The stock’s market capitalization has now valued at $65.68B. The corporation holds 14.34 million outstanding shares and its 13.14 million shares were floated in the market.
Advertisement
Cognizant Technology Solutions Corp (NASDAQ:CTSH) now has mean rating of 1.8 while 17 analyst have recommended the shares as “BUY”, 11 commented as “OUTPERFORM” and 3 commented as “HOLD”.
Many Wall Street Analysts have commented on Abbott Laboratories. The stock has a consensus analyst price target of $150.00for twelve month. The stock traded with the volume of 6.53 Million in the last trading session. The investment management firm now holds a total of 109,780 shares of Abbott Laboratories which is valued at $4,945,589.Abbott Laboratories makes up approximately 2.02% of Broderick Brian C’s portfolio. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.39% where SMA50 and SMA200 are 8.91% and 9.49% respectively. Underperform rating was given by 0 analyst and Outperform rating was given by 7 analyst.
Cognizant Technology Solutions Corp (NASDAQ:CTSH) mean estimate for revenue for the ongoing quarter ending Sep 16 is $3.47B by 21 analysts. The shares, which traded within a range of $42.92 to $44.35 during the day, are up by 31.36% in the past three months and up by 75.8% over the past six months.
While looking at the Stock’s Performance, Abbott Laboratories now shows a Weekly Performance of -0.35%, where Monthly Performance is 6.72%, Quarterly performance is 19.85%, 6 Months performance is 18.26% and yearly performance percentage is -8.64%. The stock had a trading volume of 5.4 M shares.
Company latest quarter ended on 30 Jun 2016, company announced earnings of $0.87.
Advertisement
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Established Pharmaceutical Products segment includes the worldwide sales of a line of branded generic pharmaceutical products. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, commercial laboratories and alternate-care testing sites.
